Issue #5: The FDA Already Told Its Own Panel to Say No

Back in our double issue, we flagged a meeting worth watching: on July 23 and 24, the FDA’s Pharmacy Compounding Advisory Committee sits down to decide whether seven peptides that RFK Jr. and the MAHA world have championed should get a legal path back into compounding pharmacies. The seven are BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, and Emideltide (also called DSIP). If you spend any time in the biohacking, recovery, or longevity world, you know those names.

That meeting is this Thursday and Friday. And the FDA already tipped its hand.

In briefing documents posted ahead of the meeting, FDA reviewers concluded that not one of the seven should be added to the 503A Bulks List, the regulatory list that would let pharmacies legally compound them. The advisory committee’s vote is nonbinding, but the FDA generally follows it. So going into a meeting that a lot of people framed as MAHA loosening the rules, the agency’s own staff showed up recommending a clean sweep of no.

Why the FDA says no

Reviewers ran every substance through the same four-part test: chemical characterization, history of compounding use, evidence it actually works, and safety. Nearly all seven failed the same way.

On effectiveness, the FDA found no human clinical studies at all for KPV, TB-500, and MOTS-c supporting the proposed uses. For BPC-157, the only human data was a single small trial presented as a decades-old meeting abstract, and none of it used the injection or nasal routes people actually take. On safety, because most of these are injected, reviewers repeatedly flagged immunogenicity, the risk that your body reacts to the peptide or to manufacturing impurities. Few of the submitted quality certificates even tested for impurities or bacterial endotoxins.

Then there were the substance-specific red flags. Epitalon activates telomerase, which some people sell as an antiaging feature, but the FDA noted longer telomeres are also linked to higher cancer risk and the studies were far too short to rule that out. Semax showed a possible bleeding risk and, in mice, potentiated amphetamine-driven dopamine release, a pattern the FDA associates with drugs of abuse. BPC-157 drew three adverse event reports tied to compounded injectables, including one person who developed diffuse skin and gum darkening.

How to actually read this

Two things are true at once, and it is worth holding both.

First, the FDA is not wrong that the evidence is thin. These peptides get marketed as near cure-alls for injury, gut health, sleep, and aging, and the human data does not come close to backing that. “People want it” and “it works” are different statements, and a lot of the marketing blurs the line on purpose.

Second, the restrictions have not made the demand go away. People are taking these regardless. Push them out of regulated compounding pharmacies and sourcing does not stop, it moves to overseas suppliers and “research use only” labels with no quality control. If the goal is safety, an unregulated gray market is arguably the worst outcome of all.

There is also a political wrinkle most coverage skips. These peptides are manufactured predominantly in China, which puts the MAHA push for access on a collision course with the China hawks in the same party. That tension has not gone away just because the FDA staff said no.

The bottom line

Watch the vote Thursday and Friday, but watch what the FDA does after even more closely. A no from staff plus a no from the committee would not ban anything you can already buy. It just keeps these seven in the legal gray zone they have lived in for years. The real tell will be whether the new FDA, the one that campaigned on health freedom, overrides its own scientists or defers to them. Either way, this is the clearest test yet of what MAHA means when the science and the slogans point in different directions.

Sources:

The healthiest eaters are showing up with lung cancer, and pesticides are the prime suspect. Researchers at USC’s Norris Comprehensive Cancer Center found that young, never-smoking lung cancer patients had better than average diets, scoring 65 on the Healthy Eating Index versus a national average of 57, and eating more dark greens, legumes, and whole grains than the typical American. The leading theory for the unexpected link is pesticide exposure, since conventionally grown produce and grains tend to carry higher residues than meat or dairy, and farmworkers exposed to pesticides already show elevated lung cancer rates. The findings, presented at the 2026 American Association for Cancer Research meeting, are preliminary and do not prove causation. But if you eat clean, this is the clearest argument yet for buying organic on the produce that matters most. ScienceDaily | Healthline

Ozempic dosing mistakes are flooding poison control lines. A study out of UT San Antonio found that calls to U.S. poison centers involving GLP-1 drugs jumped from roughly 1,000 to 1,500 a year before 2021 to more than 8,000 by 2023, with semaglutide alone accounting for 64 percent of them. The two most common errors were people injecting the drug daily instead of weekly, and starting at a full dose instead of titrating up. Compounded vial-and-syringe products carry extra risk because there is no pen to auto-measure the dose, so the patient draws it themselves. The researchers stress most of these errors were preventable with better patient education. As these drugs go mainstream, the failure point is not the molecule, it is how people are being handed it. ScienceDaily | UT San Antonio

Fiber may decide whether your gut helps you or ignores you. A new study found that dietary fiber determines whether beneficial gut organisms actively lower inflammation or drop into a dormant, do-nothing state. On a fiber-rich diet, they stayed active and supported an anti-inflammatory response. On a low-fiber, Western-style diet, they went dormant and the benefit disappeared, while overall microbial diversity dropped. It is one more piece of evidence that the modern low-fiber diet is not just missing a nutrient, it is switching off part of how the gut is supposed to regulate itself. ScienceDaily

A “longevity diet” points the finger at one amino acid. A USC study found that mice on a low-protein, Mediterranean-style diet lived healthier lives with less body fat and frailty, and that dialing a single amino acid, methionine, was enough to drive dramatic metabolic changes. Human data in the same work linked lower animal-protein intake to lower rates of obesity and type 2 diabetes. This one cuts against the high-protein consensus in a lot of fitness circles, so hold it loosely. It is mouse data plus population correlations, not a human trial. But the protein question is more open than gym culture admits. ScienceDaily | USC Today

The self-affirmed GRAS loophole is still open, for now. We covered this in Issue #2, and here is the update: the FDA’s proposed rule to require companies to actually notify the agency before declaring their own additives “safe” is still sitting under White House review, with a 2026 publication target but no final rule yet. Legal experts are already questioning whether the FDA even has the authority to make notification mandatory, which sets up a court fight whenever it drops. Translation: for now, companies can still put new ingredients in your food without telling anyone. The reform is real, but it is slower than the headlines suggested. Center for Science in the Public Interest | Verdant Law

That’s it for this week. If someone forwarded this to you, you can subscribe at wellnesswirereport.com. If you found it useful, forward it to someone who still thinks the FDA and the supplement aisle are on the same team.

Stay skeptical,

Carson

The Wellness Wire

Weekly health intelligence. Read more, trust less.

wellnesswirereport.com | @wellnesswirereport